Watson Christopher Mark, Crinnion Laura A, Gleghorn Lindsay, Newman William G, Ramesar Rajkumar, Beighton Peter, Wallis Gillian A
Yorkshire Regional Genetics Service and School of Medicine, University of Leeds, St James's University Hospital, Leeds, UK.
S Afr Med J. 2015 Sep 21;105(7):558-63. doi: 10.7196/SAMJnew.7917.
Beukes hip dysplasia (BHD) is an autosomal dominant disorder of variable penetrance that was originally identified in a large South African family of European origin. BHD is characterised by bilateral dysmorphism of the proximal femur, which results in severe degenerative osteoarthropathy. Previous studies mapped the disorder to a 3.34 Mb region on chromosome 4q35.
To fine-map the BHD locus and identify the disease-causing mutation by direct sequencing.
The linked BHD allele was refined to 1.33 Mb, reducing the number of candidate genes from 25 to 16. Analysis of protein coding and invariant splice-site sequences in three distantly related individuals identified a single-candidate disease-causing variant c.868T>C within exon 8 of the ubiquitin-fold modifier 1 (Ufm1)-specific peptidase 2 gene, UFSP2. The presence of this unique mutation was confirmed in all 17 affected members of the BHD family who were genotyped. The mutation segregated with the BHD phenotype in the extended family with a two-point (single marker) LOD score of 10.4 (θ=0.0 and 80% penetrance). The mutation predicts the substitution of a highly conserved amino acid, p.Tyr290His, in the encoded protein. In vitro functional assays performed using purified recombinant wild-type and mutant UFSP2 protein demonstrated that the BHD mutation abolishes UFSP2-mediated C-terminal cleavage of its substrate, Ufm1.
We report a unique UFSP2 mutation that segregates with the BHD phenotype. The predicted amino acid substitution inactivates UFSP2 proteolytic function, thus implicating the ubiquitin-fold modifier 1 cascade in this form of severe hip osteoarthropathy. The facile polymerase chain reaction-based assay we describe could be used to confirm the diagnosis of BHD, or for presymptomatic testing of members of the extended BHD family.
比克斯髋关节发育不良(BHD)是一种常染色体显性疾病,其外显率可变,最初在一个起源于欧洲的南非大家庭中被发现。BHD的特征是双侧股骨近端畸形,这会导致严重的退行性骨关节炎。先前的研究将该疾病定位到4号染色体q35区域的一个3.34 Mb的区间。
对比克斯髋关节发育不良(BHD)基因座进行精细定位,并通过直接测序确定致病突变。
连锁的BHD等位基因被精细定位到1.33 Mb,使候选基因数量从25个减少到16个。对三个远亲个体的蛋白质编码和不变剪接位点序列进行分析,在泛素折叠修饰因子1(Ufm1)特异性肽酶2基因(UFSP2)的第8外显子中鉴定出一个单一候选致病变异c.868T>C。在所有接受基因分型的17名BHD家族受影响成员中均证实了该独特突变的存在。在这个大家庭中,该突变与BHD表型共分离,两点(单标记)对数似然比分数为10.4(θ=0.0,外显率80%)。该突变预测编码蛋白中一个高度保守的氨基酸p.Tyr290His会被替换。使用纯化的重组野生型和突变型UFSP2蛋白进行的体外功能分析表明,BHD突变消除了UFSP2介导的其底物Ufm1的C末端切割。
我们报告了一个与BHD表型共分离的独特的UFSP2突变。预测的氨基酸替换使UFSP2的蛋白水解功能失活,从而表明泛素折叠修饰因子1级联反应与这种严重的髋部骨关节炎形式有关。我们描述的基于聚合酶链反应的简便检测方法可用于确诊BHD,或对BHD大家庭成员进行症状前检测。